Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg

ClinicalTrials.gov ID: NCT00918138

Public ClinicalTrials.gov record NCT00918138. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 4-Week, Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy of Saxagliptin in Combination With Metformin XR 1500 mg Versus Up-titrated Metformin XR to 2000 mg in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise and a Stable Dose of Metformin XR 1500 mg

Study identification

NCT ID
NCT00918138
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
219 participants

Conditions and interventions

Interventions

  • Saxagliptin Drug
  • Metformin XR Drug
  • Placebo matching Metformin XR Drug
  • Placebo matching Saxagliptin Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 78 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2009
Primary completion
Apr 30, 2010
Completion
Apr 30, 2010
Last update posted
May 20, 2015

2009 – 2010

United States locations

U.S. sites
12
U.S. states
9
U.S. cities
12
Facility City State ZIP Site status
Dedicated Phase I, Inc. Phoenix Arizona 85013
Pacific Sleep Medicine Services (Avastra Clinical Trials) Redlands California 92373
Orange County Research Center Tustin California 92780
Clinical Research Of South Florida Coral Gables Florida 33134
Palm Springs Research Institute Hialeah Florida 33012
Healthcare Clinical Data, Inc. North Miami Florida 33161
River Birch Research Alliance, Llc Blue Ridge Georgia 30513
Jasper Clinic, Inc. Kalamazoo Michigan 49007
Clinilabs, Inc. New York New York 10019
Medpace Clinical Pharmacology Unit Cincinnati Ohio 45212
Clinical Trials Of Texas Inc. San Antonio Texas 78229
Advanced Clinical Research West Jordan Utah 84088

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00918138, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 20, 2015 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00918138 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →